Atibuclimab (IC14) safely reduces inflammation, BNP, and improves LVEF in acute decompensated heart failure

Acute decompensated heart failure (ADHF) is a critical condition often exacerbated by systemic inflammation, contributing to adverse cardiovascular outcomes. Current standard-of-care primarily focuses on symptom management and hemodynamic stabilization, but often fails to adequately address the underlying inflammatory drivers. CD14, a pattern recognition receptor, plays a key role in innate immunity and inflammation, making its blockade a promising therapeutic strategy to mitigate the inflammatory cascade in ADHF and potentially improve cardiac function.

This phase Ib, open-label, single-arm pilot study enrolled adults hospitalized for acute decompensated heart failure with reduced ejection fraction and systemic inflammation. Participants received a single intravenous infusion of IC14. The primary endpoint was safety and tolerability of Atibuclimab (IC14). Exploratory endpoints included CD14 receptor occupancy, C-reactive protein (CRP), B-type natriuretic peptide (BNP) levels, and clinical outcomes, including left ventricular ejection fraction (LVEF) assessment.

Atibuclimab (IC14) demonstrated excellent tolerability, with no unexpected treatment-related serious adverse events reported. The intervention successfully achieved sustained CD14 receptor occupancy, indicating effective target engagement. Treatment was associated with a notable reduction in systemic inflammation, as evidenced by changes in inflammatory markers. Furthermore, patients exhibited lower natriuretic peptide levels, specifically BNP, a key biomarker for heart failure severity and prognosis. Most importantly, the study observed an improvement in left ventricular ejection fraction (LVEF), suggesting a positive impact on cardiac function. These findings collectively support the biological activity and safety profile of CD14 blockade in this patient population.

Atibuclimab was well tolerated, with no unexpected treatment-related serious adverse events, and was associated with sustained CD14 receptor occupancy, reduction in systemic inflammation, lower natriuretic peptide levels, and improvement in left ventricular ejection fraction.